Senti Biosciences (NASDAQ:SNTI – Get Rating) is one of 283 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Senti Biosciences to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Valuation & Earnings
This table compares Senti Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Senti Biosciences||$4.29 million||-$58.21 million||-0.47|
|Senti Biosciences Competitors||$692.05 million||$85.96 million||-2.49|
Senti Biosciences’ peers have higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
This table compares Senti Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Senti Biosciences Competitors||-4,068.84%||-137.69%||-41.93%|
This is a summary of current ratings and price targets for Senti Biosciences and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Senti Biosciences Competitors||1066||4143||11197||176||2.63|
Senti Biosciences currently has a consensus price target of $4.50, indicating a potential upside of 358.76%. As a group, “Biological products, except diagnostic” companies have a potential upside of 67.55%. Given Senti Biosciences’ higher possible upside, equities research analysts clearly believe Senti Biosciences is more favorable than its peers.
Institutional and Insider Ownership
40.8% of Senti Biosciences shares are owned by institutional investors. Comparatively, 46.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 8.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 15.5% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Senti Biosciences peers beat Senti Biosciences on 7 of the 13 factors compared.
Senti Biosciences Company Profile
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells, while sparing healthy cells in the body. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.